(Press-News.org) Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.
The authors at King’s College London say that using the radiotracer – an injected compound used in PET scans – could help inform doctors that a patients aggressive cancer will not respond to chemotherapy before treatment is given. This would prevent the patients receiving unnecessary treatment and provide them with alternative options that will give them the best chance of beating the disease.
The paper, published today in Nature Communications, shows therapy-resistant non-small cell lung cancer tumours ’lit up like a Christmas tree’ on PET scans when the radiotracer was injected.
Tim Witney, a Professor of Molecular Imaging from King’s College London, and lead researcher of the study said: “Currently, there is no quick and early method that shows whether malignant tumours are resistant to treatment. Time is essential for patients with lung cancer, and many cannot afford to wait to see if chemotherapy is working. We wanted to increase the window of opportunity for treatment for these patients – giving them more choice and a better chance of survival.”
Non-small cell lung cancer is the most common type of lung cancer in the UK and 47,000 people are diagnosed with it every year. Standard care includes surgery, radiotherapy, chemotherapy and immunotherapy, but despite advancements in treatment, survival rates have not improved much in the past decade.
Typically, patients with lung cancer will be started on a treatment plan – such as chemotherapy – and then wait twelve weeks to have a CT or PET scan to see whether the treatment has shrunk the tumour, or the tumour has stayed the same or has grown. But twelve weeks can often be too late to change course of treatment and end-of-life care is frequently the only option.
Researchers from King’s re-purposed a radiotracer, currently used as a diagnostic tool in clincal trials in the USA and South Korea, to show treatment-resistant tumours on PET scans. The molecule targets xCT, a tumour-associated protein which is present on therapy-resistant tumours. In images from the study, PET scans of animal models show tumour-resistant cancer cells light up brighter compared to tumours responsive to treatment.
The authors will now trial this in humans with a phase I clinical trial beginning in January at St Thomas’ Hospital in London. The trial will recruit 35 patients and use the total-body PET scanner at the hospital’s PET Centre to see xCT with imaging before and after patients receive treatment.
Professor Witney added: “Our study is the cumulation of five years of work. Frequently, cancer patients find out too late that the treatment they’re on does not work. The radiotracer 18F-FSPG binds to the tumour-resistant cells and lights up like a Christmas tree in imaging – clearly showing the aggressive cancer. With this technique, we can give the right treatment to the right patient, making it more cost-efficient for the NHS and providing hope for patients with aggressive tumours.”
In the same paper, researchers also show that xCT can also be targeted by an antibody-drug conjugate, a new class of drug designed as a targeted treatment for therapy-resistant cancer cells, which selectively kills these cells whilst minimising unwanted toxicity. While research is still in the early stages, the authors hope this could offer a glimmer of hope for patients with the most aggressive and difficult-to-treat cancers, including lung, pancreatic and breast cancers.
The study was funded through a Wellcome Trust Senior Research Fellowship and by UKRI under the UK government’s Horizon Europe funding guarantee.
Read the paper ‘Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography’ in Nature Communications.
END
Scientists develop new scans that light-up aggressive cancer tumors for better treatment
2024-12-17
ELSE PRESS RELEASES FROM THIS DATE:
The longevity factor Foxo3 mediates “unfit” cell elimination to ensure healthy body construction
2024-12-17
Osaka, Japan – From the very moment an egg is fertilized, life begins with a remarkable process: cells start dividing and replicating to make copies of themselves. Yet this process is not flawless. Errors can occur when genetic material is copied, creating “unfit” cells that don’t work properly. To keep development on track, cells employ a fascinating quality control system called cell competition. However, much about this mechanism remains unclear.
Now, in a study recently published in Nature ...
Researchers demonstrate high accuracy of observation device that can be dropped into typhoon without parachute
2024-12-17
Researchers in Japan have demonstrated the high accuracy of their newly developed typhoon observation device, which is designed to drop from an aircraft into the eye of a typhoon. The results were published in the journal Scientific Online Letters on the Atmosphere (SOLA).
Dropped from aircraft, the dropsonde, a small, single-use instrument, measures and transmits atmospheric data, including temperature, humidity, and wind speed, as it falls. The new dropsonde, iMDS-17, weighs only 130 grams and is made mainly of a biodegradable ...
Positive results of the clinical trial of a drug to improve cognitive function in Down syndrome
2024-12-17
The ICOD (Improving Condition in Down syndrome) project, a pioneering study in addressing the cognitive difficulties associated with Down syndrome, has demonstrated the safety of treatment with the molecule AEF0217, developed by the French biotech Aelis Farma, as well as its effectiveness in improving cognitive function in these people. The study was led by the Research Institute of the Hospital del Mar.
This phase of the trial (phase 1/2 of the project), funded by the European Union under the Horizon 2020 R+D programme and Aelis Farma, has been carried out with 29 people with Down syndrome between 18 and ...
Insurance challenges limit psychologists’ capacity to address ongoing mental health needs
2024-12-17
Although demand for mental health treatment remains high, administrative and financial barriers are preventing many psychologists from participating in insurance networks, according to the American Psychological Association’s 2024 Practitioner Pulse Survey. Barriers by many insurance companies can make it more difficult for psychologists to remain in-network and for patients to access the care they need, exacerbating the ongoing mental health crisis.
This annual survey, which was conducted among 853 psychologists in September 2024, by APA and its companion organization APA Services ...
Genomic Press transforms scientific publishing, inspired by moon-bound color story
2024-12-17
SAN BERNARDINO, California, USA, 17 December 2024 - In a compelling Genomic Press Interview, Editor-in-Chief Dr. Julio Licinio reveals how a children's book about a lonely color has shaped the innovative vision of scientific publisher Genomic Press. The story of Flicts, penned by renowned Brazilian artist Ziraldo Alves Pinto, has become more than just a brand element – it represents a revolutionary approach to academic publishing.
"Sometimes the ideas that don't fit anywhere else are precisely the ones that help us reach the stars," explains Dr. Licinio, highlighting the publisher's mission to support ...
Addiction neuroscience leader reveals how brain circuits drive behavioral disorders
2024-12-17
CHARLESTON, South Carolina, USA, 17 December 2024 - In a comprehensive Genomic Press Interview published today in Brain Medicine, renowned neuroscientist Dr. Peter Kalivas reveals crucial insights into how brain circuits drive addictive behaviors and discusses potential new drug targets for treating behavioral disorders.
Dr. Kalivas, Distinguished University Professor at the Medical University of South Carolina, has transformed our understanding of addiction neuroscience through his pioneering work on the tetrapartite synapse - a complex cellular structure that includes neurons, astroglia, and the extracellular matrix. His ...
Neuroscientist maps brain's fundamental calculations in learning and social interaction
2024-12-17
PHILADELPHIA, Pennsylvania, USA, 17 December 2024 - In a comprehensive Genomic Press Interview, Dr. Munir Gunes Kutlu, Assistant Professor at Temple University's Center for Substance Abuse Research, unveils revolutionary findings about how our brains process fundamental learning calculations and social interactions.
"Our research has identified specific neural mechanisms that transform sensory inputs into behavioral outputs," says Dr. Kutlu. "We've discovered that the brain's dopamine system works in more sophisticated ways than previously understood, particularly in how it processes information about environmental cues and rewards."
The interview, published ...
Attitudes toward psychedelic therapy reveal both promise and caution, new study finds
2024-12-17
ATLANTA, Georgia, USA, 17 December 2024 - In a comprehensive Genomic Press Interview with researchers from Emory University, a new study published today reveals complex attitudes toward psychedelic therapy, with detailed statistics showing both strong support for potential benefits and significant awareness of risks.
The research, published in the journal Psychedelics, surveyed 178 attendees at an academic conference focused on psychedelics and spiritual care. Among participants, 32 were active psychedelic ...
Leuven researchers discover new connectivity rules in the brain’s visual network
2024-12-17
Leuven, Belgium, 17 December 2024 – Researchers at Neuro-Electronics Research Flanders (NERF), led by Prof. Vincent Bonin, have published two new studies uncovering how visual information is processed and distributed in the brain. The studies reveal the complexity and flexibility of visual information processing in the brain.
The visual cortex, a key region for interpreting and processing visual input, plays a crucial role in shaping what we see. Vincent Bonin, a professor at KU Leuven and group leader at NERF, studies the neural circuits that process sensory information. "We often think of visual processing ...
Patients whose allergies cause the sniffles have different fungi living in their noses, compared to healthy people
2024-12-17
Nearly a quarter of Portuguese adults have allergies that cause a runny nose. This respiratory disease, formally called allergic rhinitis and frequently associated with asthma, is a common problem around the world, and the upper airway is a key target for research into the underlying disease processes. Now a global team of researchers has discovered that patients with allergy-induced sniffles and asthma have different fungal colonies or mycobiomes in their noses, suggesting potential lines of enquiry for future treatments.
“We showed that allergic rhinitis ...